Human Papillomavirus Protein E7 Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2028

The global human papillomavirus protein E7 market is expected to grow at a significant CAGR during the forecast period (2022-2028). Human papillomavirus (HPV) infections are a collection of skin infections that affect the anus, cervix, and mouth, among other regions of the body. People of various ages are discovered to be affected by various types of warts. The most common and contagious of all warts, genital warts spread by skin-to-skin contact. In children, warts are frequently left untreated. In rare circumstances, warts can be removed by applying drugs directly to the lesions. In order to prevent future infections, HPV vaccination is suggested, however, it is not a treatment.

To Request a Sample of our Report on Human Papillomavirus Protein E7 Market: https://www.omrglobal.com/request-sample/human-papillomavirus-protein-e7-market

The infected virus by entering the body by a cut, abrasion, or a small tear in the skin. Skin-to-skin contact is the most common way for the virus to spread. In the 1990s, epidemiologic studies indicating a consistent link between HPV and cervical cancer were published; more recently, HPV has been linked to other mucosal malignancies. In the US, a quadrivalent vaccination to prevent infection with four forms of HPV was approved in 2006, followed by a bivalent vaccine in 2009 and a 9-valent vaccine in 2014. The Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute (NCI) and the National Program of Cancer Registries of the Centers for Disease Control and Prevention (CDC) offer data on the number of HPV malignancies in the US. The rise in the number of infections caused by HPV is contributing to the growth of the market. Annually, as per CDC, 43,999 HPV-related malignancies are reported, including 24,886 cases in women and 19,113 cases in men. The most prevalent diseases linked to HPV are projected to be 10,900 cervical cancers in women and 11,300 oropharyngeal cancers in males, according to gender. HPV is also responsible for 91% of anal cancers, 69% of vulvar cancers, 75% of vaginal cancers, 63% of , and 70% of oropharyngeal cancers, in addition to cervical cancer.

Market Coverage

· The market number available for - 2021-2028

· Base year- 2021

· Forecast period- 2022-2028

Segment Covered-

· By Type

· By Application

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: Inovio Pharmaceuticals, Inc., and Genexine, Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Human Papillomavirus Protein E7 Market is Available @ https://www.omrglobal.com/industry-reports/human-papillomavirus-protein-e7-market

Global Human Papillomavirus Protein E7 Market Report by Segment

By Type

· CUE-201

· BLSILSB-710c

· Others

By Application

· Anal Cancer

· Lung Cancer

· Rectal Cancer

· Others

Global Human Papillomavirus Protein E7 Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.